Ñõ»¯Ö¬ÖÊ·´Ó¦ÊÇÖ¸¶à²»±¥ºÍÖ¬·¾Ëᱬ·¢×Ô¶¯Ñõ»¯£¬»òÔÚÏìÓ¦µÄø´Ù´ß»¯×÷ÓÃÏÂÌìÉúһϵÁÐÑõ»¯´úлÎïµÄÀú³Ì¡£Ñõ»¯Ö¬ÖÊ·´Ó¦Àú³Ì»áÌìÉúһϵÁеĴúлÎïÖÊ£¬Ò²³ÆΪ֬ÖʽéÖÊ£¬ÕâÀàÎïÖÊÔÚÉúÔËÆø¶¯ÖÐÆðןÜÊÇÖ÷ÒªµÄµ÷¿Ø×÷Ó㬰üÀ¨Ñ×Ö¢·´Ó¦¡¢ÃâÒß·ÀÓù¡¢ÄÚÉø͸µ÷Àí£¬ÒÔ¼°´úлӦ¼¤µÈ¡£Ñо¿·¢Ã÷Ñõ»¯Ö¬ÖÊ´úлÎïÔÚÖ×Áö¡¢Éñ¾ÍËÐÐÐÔ¼²²¡¡¢ÐÄѪ¹Üϵͳ¼²²¡¡¢Ïû»¯ÏµÍ³¼²²¡¡¢ÃÚÄòϵͳ¼²²¡µÈ¼²²¡µÄ±¬·¢Éú³¤Àú³ÌÖоù¶¼Æðµ½ÁËÖ÷ÒªµÄµ÷¿Ø×÷Óá£
Ñõ»¯Ö¬ÖÊÊǺ¬Ñõ¶à²»±¥ºÍÖ¬·¾ËᣬȪԴÓÚÒ¶ÂÌÌåĤÖаëÈéÌÇÖ¬µÄõ£»ù¡£Ö²ÎïÖ¬ÑõºÏø (Lipoxygenase, LOX) »á´ß»¯ÑÇÓÍËá (C18:2) ºÍÑÇÂéËá (C18:3) µÄË«ÑõºÏ£¬ÐγÉÏìÓ¦µÄÇâ¹ýÑõÖ¬·¾Ëá (Fatty Acid Synthase, FAs)£¬ÓÃÓÚÑõ»¯Ö¬Öʺϳɣ¬ËüÃǶԵ÷ÖÎÖ²ÎïÉú³¤·¢ÓýÒÔ¼°¶Ô²¡ÔÌåºÍ·ÇÉúÎïвÆȵķ´Ó¦ºÜÖ÷Òª¡£Ñõ»¯Ö¬ÖÊ»¹¼ÓÈëвÆÈÐźÅתµ¼£¬µ÷ÀíвÆÈÓÕµ¼µÄ»ùÒò±í´ï£¬²¢ÓëÖ²Îïϸ°ûÖеÄÆäËûÐźÅͨ·Ï໥×÷Ó㬰üÀ¨Ö²ÎDËØÉú³¤ËØ¡¢³àùËØ¡¢ÒÒÏ©ºÍÍÑÂäËáµÄÐźÅͨ·¡£
ͬλËØÄڱ궨Á¿£¬¶¨ÐÔ¶¨Á¿×¼
¿Éͬʱ¼ì²â130+ÖÖÎïÖÊ
Ö²Îï×éÖ¯£º1 g/sample
¶¯Îï¼°ÁÙ´²×éÖ¯±ê±¾£º200 mg/sample
ѪÇ塢Ѫ½¬£º200 ¦ÌL/sample
ϸ°û¡¢Î¢ÉúÎ1X 107 cells/sample
·à±ã¡¢³¦µÀÄÚÈÝÎ200 mg/sample
Òºµª»ò-80¡ãCÉúÑÄ£»×ãÁ¿¸É±ùÔËÊ䣬×èÖ¹Öظ´¶³ÈÚ
? ¼ì²âƽ̨
Qtrap 6500+, Sciex
? ͨÀýÏîÄ¿ÖÜÆÚ
ʵÑé¼ì²â£º44¸ö×ÔÈ»ÈÕ£¨´ÓÊÕµ½¿Í»§Ô¤¸¶¿î²¢ÊÕµ½ÑùÆ·Ö®ÈÕÆð£©
Êý¾ÝÆÊÎö£º5¸ö×ÔÈ»ÈÕ
- ÐÄѪ¹Ü¼²²¡
- Ò©Îï°Ðµã
? °ÐÏòÖ¬ÖÊ×éѧչÏÖÁ˼±ÐÔʧ´ú³¥ÆÚ¸ÎÓ²»¯»¼ÕßµÄÖ¬ÖʽéÖÊת±ä
Ñо¿¹¤¾ß£º ÈËѪ½¬
ÆÚ¿¯£º Theranostics
Ó°ÏìÒò×Ó£º 9.264
ʱ¼ä£º 2020Äê
Âý¼Ó¼±ÐÔ¸ÎË¥½ß(Acute on Chronic Liver Failure, ACLF)ÊÇÒ»ÖÖз¢Ã÷µÄ×ÛºÏÕ÷£¬¸ÎÓ²»¯¼±ÐÔʧ´ú³¥ (Acute Decompensation, AD) »¼Õß¾³£Éú³¤ÎªÂý¼Ó¼±ÐÔ¸ÎË¥½ß(Acute on Chronic Liver Failure, ACLF)£¬ÆäÌصãÊÇÈ«ÉíÑ×Ö¢·´Ó¦ÑÏÖØ¡¢¶àÆ÷¹Ù¹¦Ð§Ë¥½ßºÍ¶ÌÆÚéæÃüÂʸߡ£Ñõ»¯Ö¬ÖÊÊÇÔÚÑ×Ö¢ºÍÃâÒßÖÐÆðÖ÷Òª×÷ÓõÄÄÚÔ´ÐÔÐźŷÖ×Ó£¬¿ÉÊÇÔÚACLFÖеĴúлÑо¿²¢Î´¼¸¡£
? Ñо¿Ë¼Ð÷
? Ч¹ûչʾ
1¡¢PUFA¼°Ã¸¼ì²â
×ܲ»±¥ºÍÖ¬·¾ËẬÁ¿½µµÍ£¬²¢ÇÒAA/EPA±ÈÀý×÷ΪȫÉíÑ×Ö¢µÄ±ê¼ÇÎïÔÚ¼²²¡×éÖÐÏÔÖøÉý¸ß£¬ÕâÓëACLF»¼Õß»áÌåÏÖ³öÈ«ÉíÑ×Ö¢¼ç¸ºÔöÌíµÄÊÂʵһÖ¡£
2¡¢Ñõ»¯Ö¬Öʼì²âÆÊÎö
½ÃÕýÐÔ±ðºÍÄêËêºó£¬É¸Ñ¡³ö16¸öÏÔÖøת±äµÄÖ¬ÖÊ¿ÉÒÔÓÃÓÚÇø·Ö¿µ½¡×éºÍ¼²²¡×é¡£
3¡¢LTE4¿É·´Ó¦¼²²¡ÑÏÖØˮƽ
ÔÚɸѡ³öµÄ²î±ðÎïÖУ¬LTE4µÄº¬Á¿Ëæ׿²²¡µÄÑÏÖØˮƽÔöÌí£¬AD×é±È¿µ½¡×麬Á¿¸ß¶øACLF×é±ÈAD×é¸ß£¬²¢ÇÒACLF3¼¶ÖеÄLTE4º¬Á¿¸ßÓÚACLF1¼¶ºÍ2¼¶¡£
4¡¢¹ØÁªÆÊÎö
ͨ¹ý¹ØÁªÆÊÎö»ñµÃÑõ»¯Ö¬ÖÊÓë´ó¶¼Ñ×Ö¢Òò×ÓºÍϸ°ûéæÃü³ÊÕýÏà¹Ø£¬µ«ÓëLXA5³Ê¸ºÏà¹Ø£¬LXA5ÊÇÒ»ÖÖ¿¹Ñ׺ʹÙÆÊÎöµÄÖ¬ÖʽéÖÊ¡£Ñõ»¯Ö¬ÖÊÓëLTE4ºÍLXAÏà¹ØÐÔ½ÏÇ¿¡£LTE4ÊÇΨһÓëÑ×ÐÔϸ°ûÒò×Ó/Ç÷»¯Òò×Ó³ÊÏÔ×ÅÕýÏà¹ØµÄÖ¬ÖʽéÖÊ¡£²¢ÇÒLTE4»¹ÓëADºÍACLF»¼ÕßµÄϸ°ûéæÃü±ê¼ÇÎï³ÊÕýÏà¹Ø£¬Åú×¢LTE4¿ÉÄÜÓë·ÇµòÍöÐÎʽÏà¹Ø¡£
? ²Î¿¼ÎÄÏ×
L¨®pez-Vicario C, Checa A, Urdangarin A, Aguilar F, Alcaraz-Quiles J, Caraceni P, Amor¨®s A, Pavesi M, G¨®mez-Cabrero D, Trebicka J, Oettl K, Moreau R, Planell N, Arroyo V, Wheelock CE, Cl¨¤ria J. Targeted lipidomics reveals extensive changes in circulating lipid mediators in patients with acutely decompensated cirrhosis. J Hepatol. 2020 Oct;73(4):817-828. doi: 10.1016/j.jhep.2020.03.046. Epub 2020 Apr 12. PMID: 32294533.